- Peptinovo Biopharma has entered a strategic manufacturing partnership with Ardena, a specialist pharmaceutical CDMO and CRO.
- The collaboration supports Peptinovo’s preparation for human clinical trials of its PALM™ nanotechnology-based cancer therapy by the end of the year.
Peptinovo Biopharma has announced a manufacturing partnership with Ardena, a pharmaceutical contract development and manufacturing organisation (CDMO) and bioanalytical contract research organisation (CRO). Under the agreement, Ardena will manufacture Peptinovo’s cancer drug-delivery nanotechnology in preparation for human clinical trials planned for later this year.
The partnership marks a key milestone for Peptinovo as it transitions its PALM™ (Peptide-Assisted Lipid Micelle) platform from laboratory research to clinical production. The collaboration ensures the manufacturing stability, scalability, and quality needed to support global clinical development.
“Partnering with Ardena is a huge step forward for Peptinovo because it demonstrates we have achieved the level of manufacturing stability that is so vital in this industry.”
Peptinovo Biopharma CEO Steve Tokarz
Peptinovo’s PALM™ technology is designed to deliver chemotherapy drugs more precisely to tumour sites, reducing toxicity and enhancing therapeutic outcomes. Ardena will apply its experience in nanomedicine development, analytical capabilities, and project management to support the advancement of the programme into clinical testing in Australia.
Ardena COO Gerjan Kemperman said the company was pleased to support Peptinovo’s work, noting that the collaboration aims to accelerate the development of precision medicines and translate scientific innovation into clinical benefit.
